Join our daily newsletter At The Bell to receive exclusive market insights
- Prescient Therapeutics (PTX) unveils its new cell therapy manufacturing enhancement technology, CellPryme-M
- CellPryme-M is a platform technology that produces superior cells which are able to withstand cancer-killing activity for a longer duration than conventional CAR-T cells
- The company will seek to license CellPryme-M to other cell therapy companies to enhance conventional CAR-T programs and enter collaborations with external parties
- In a show of confidence, Prescient says it will be its own first customer by using the therapy to enhance its internal programs
- Shares in Prescient Therapeutics are down 9.09 per cent to $0.20 as of 12:30 pm AEST
Prescient Therapeutics (PTX) has unveiled its new cell therapy manufacturing enhancement technology, CellPryme-M.
CellPryme-M is a platform technology that produces superior cells during the cell manufacturing process. These cells are said to be less prone to exhaustion, which enables it to withstand cancer-killing activity for a longer period of time, and are capable of improved tumour trafficking and penetrance, compared to the current generation of CAR-T cells.
CellPrymeM CAR-T cells were also shown to perform better than conventional CAR-T cells in highly aggressive solid cancer models, and is now ready for use in clinical studies.
Prescient said it plans to use CellPryme-M to enhance the cells used in its breakthrough OmniCAR programs.
The clinical stage oncology company will seek to license CellPryme-M to other cell therapy companies to enhance conventional CAR-T programs and enter collaborations with external parties.
“CellPryme-M also opens up an entirely new business opportunity to license CellPryme-M to other cell therapy companies,” Prescient Managing Director and CEO Steven Yatomi-Clarke said.
“It requires minimal intervention into existing and emerging manufacturing process and therefore represents a relatively low implementation hurdle. This opens up real commercial opportunities for Prescient to incorporate CellPryme-M into third party manufacturing processes.”
“However, in a real show of confidence, Prescient will be it is own first customer by using it to enhance its internal OmniCAR programs, to combine next-gen CAR-T capabilities with superior cell phenotypes,” Steven Yatomi-Clarke said.
Shares in Prescient Therapeutics are down 9.09 per cent to $0.20 as of 12:30 pm AEST.
